MedPath

Xtl Biopharmaceuticals

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:1
Completed:0

Trial Phases

2 Phases

Phase 1:2
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 2
2 (50.0%)

A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Phase 2
Terminated
Conditions
Chronic Peripheral Neuropathy Pain in Diabetics
Interventions
First Posted Date
2008-01-18
Last Posted Date
2009-06-30
Lead Sponsor
XTL Biopharmaceuticals
Target Recruit Count
250
Registration Number
NCT00597649
Locations
🇺🇸

Four Rivers Clinical Research, Paducah, Kentucky, United States

Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes

Phase 2
Conditions
Diabetic Peripheral Neuropathy
Interventions
First Posted Date
2007-11-04
Last Posted Date
2007-11-04
Lead Sponsor
XTL Biopharmaceuticals
Target Recruit Count
336
Registration Number
NCT00553592
Locations
🇺🇸

Four Rivers Clinical Research, Paducah, Kentucky, United States

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

Phase 1
Conditions
Hepatitis C
First Posted Date
2006-03-09
Last Posted Date
2007-03-07
Lead Sponsor
XTL Biopharmaceuticals
Target Recruit Count
36
Registration Number
NCT00300807
Locations
🇺🇸

Indiana University School of Medicine, Indianapolis, Indiana, United States

🇺🇸

Mt Sinai School of Medicine, New York, New York, United States

🇺🇸

University Of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 2 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath